Leleu_INSURE_ITT_Supplementary_material.docx (157.79 kB)

INSURE: A pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice - supplementary material

dataset

posted on 2024-01-10, 09:58 authored by Xavier Leleu, Hans C. Lee, Jeffrey A. Zonder, Margaret Macro, Karthik Ramasamy, Cyrille Hulin, Jiri Silar, Matyas Kuhn, Kaili Ren, Nawal Bent-Ennakhil, Dasha Cherepanov, Dawn Marie Stull, Evangelos Terpos

Supplementary methods, tables and figures

Funding

Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA, (Grant / Award Number

History

Usage metrics

Keywords

effectiveness ixazomib ixazomib-lenalidomide-dexamethasone IRd multiple myeloma pooled analysis progression-free survival proteasome inhibitor relapsed/refractory routine clinical practice time-to-next treatment

Licence

CC BY-NC-ND 4.0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM